Medindia

X

Vermillion, Inc. to Host Teleconference and Webcast on Thursday, August 30, 2007 at 9:00 a.m. Eastern

Thursday, August 30, 2007 General News J E 4
Advertisement
FREMONT, Calif., Aug. 29 Vermillion, Inc.(Nasdaq: VRML), will host a teleconference and webcast on Thursday, August 30at 9:00 a.m. Eastern Time to discuss its name change and provide an update onbusiness developments. To access the live conference call via phone, dial(877) 325-7371 from the United Statesand Canadaor (706) 634-0768internationally. The conference ID is 21347583. Please dial-in approximatelyten minutes prior to the start of the call. Additionally, you may access thelive and subsequently archived webcast of the conference call from theInvestor Relations section of the Company's website athttp://www.vermillion.com. Please connect to the web site at least 15 minutesprior to the call to allow for any software download that may be necessary.

(Audio: http://www.videonewswire.com/event.asp?id=42105)

A telephone replay will be available beginning approximately two hoursafter the call through Sept 13, 2007 and may be accessed by dialing(800) 633-8284 from the United States and Canada or (+1 402) 977-9140internationally. The replay passcode is 21347583. An archived replay of thewebcast will be available until the next quarterly call.

About Vermillion, Inc.

Vermillion, Inc. is dedicated to the discovery, development andcommercialization of novel high-value diagnostic tests that help physiciansdiagnose, treat and improve outcomes for patients. Vermillion, along with itsprestigious scientific collaborators, has ongoing diagnostic programs inoncology/hematology, cardiology and women's health with an initial focus inovarian cancer. Based in Fremont, California, more information aboutVermillion can be found on the Web at http://www.vermillion.com.

SOURCE Vermillion, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Nektar Therapeutics Appoints Lutz Lingnau as New B...
S
DURECT Corporation to Present at the NewsMakers in...